Abstract

There is no currently licensed vaccine for respiratory syncytial virus (RSV) despite being the leading cause of lower respiratory tract infections in children. Children previously immunized with a formalin-inactivated RSV (FI-RSV) vaccine exhibited enhanced respiratory disease following natural RSV infection. Subsequent studies in animal models have implicated roles for CD4 T cells, eosinophils and non-neutralizing antibodies in mediating enhanced respiratory disease. However, the underlying immunological mechanisms responsible for the enhanced respiratory disease and other disease manifestations associated with FI-RSV vaccine-enhanced disease remain unclear. We demonstrate for the first time that while CD4 T cells mediate all aspects of vaccine-enhanced disease, distinct CD4 T cell subsets orchestrate discrete and specific disease parameters. A Th2-biased immune response, but not eosinophils specifically, was required for airway hyperreactivity and mucus hypersecretion. In contrast, the Th1-associated cytokine TNF-α was necessary to mediate airway obstruction and weight loss. Our data demonstrate that individual disease manifestations associated with FI-RSV vaccine-enhanced disease are mediated by distinct subsets of CD4 T cells.

Highlights

  • Respiratory syncytial virus (RSV) is the leading cause of hospitalization in infants and young children [1,2,3]

  • We sought to determine the specific immunological mechanisms that mediate formalin-inactivated RSV (FI-RSV) vaccine-enhanced disease (VED) to provide a framework to evaluate factors associated with disease exacerbation

  • Since the presence of an elevated number of eosinophils in both the lung and peripheral blood was highlighted in the initial vaccine trial reports, the development of pulmonary eosinophilia has become a hallmark of the enhanced respiratory disease (ERD) associated with FI-RSV vaccine-enhanced disease (VED) [4,5,6,7]

Read more

Summary

Introduction

Respiratory syncytial virus (RSV) is the leading cause of hospitalization in infants and young children [1,2,3]. Reexamination of the human autopsy specimens from the initial FI-RSV vaccine trials revealed only 1–2% of the total cellular infiltrate in the airways were eosinophils [12]. This observation, in conjunction with similar findings in lung sections from FI-RSV-immunized cotton rats, an alternative model of FI-RSV ERD, has raised questions concerning the role eosinophils play during FI-RSV VED [12]. It remains unclear if eosinophils directly contribute to the severe immunopathology associated with FI-RSV ERD

Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call